Sana Biotechnology Company Insiders
| SANA Stock | USD 3.85 0.06 1.58% |
Sana Biotechnology employs about 194 people. The company is managed by 20 executives with a total tenure of roughly 453 years, averaging almost 22.0 years of service per executive, having 9.7 employees per reported executive. Analysis of Sana Biotechnology's management performance can provide insight into the company performance.
Sana Biotechnology Management Team Effectiveness
The company has return on total asset (ROA) of (0.239) % which means that it has lost $0.239 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9611) %, meaning that it created substantial loss on money invested by shareholders. Sana Biotechnology's management efficiency ratios could be used to measure how well Sana Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities.Sana Biotechnology shows a total of 266.37 Million outstanding shares. The majority of Sana Biotechnology outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Sana Biotechnology to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Sana Biotechnology. Please pay attention to any change in the institutional holdings of Sana Biotechnology as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Sana Biotechnology in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Sana Biotechnology, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Sana Biotechnology Workforce Comparison
Sana Biotechnology is rated fifth in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 2,113. Sana Biotechnology holds roughly 194 in number of employees claiming about 9% of equities under Health Care industry.
Sana Biotechnology Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sana Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sana Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Sana Biotechnology insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Susan Wyrick over two weeks ago Disposition of 3250 shares by Susan Wyrick of Sana Biotechnology subject to Rule 16b-3 | ||
Susan Wyrick over a month ago Disposition of 2407 shares by Susan Wyrick of Sana Biotechnology at 4.27 subject to Rule 16b-3 | ||
Susan Wyrick over a month ago Disposition of 7500 shares by Susan Wyrick of Sana Biotechnology subject to Rule 16b-3 | ||
Susan Wyrick over two months ago Disposition of 873 shares by Susan Wyrick of Sana Biotechnology at 5.22 subject to Rule 16b-3 | ||
Susan Wyrick over two months ago Disposition of 3400 shares by Susan Wyrick of Sana Biotechnology subject to Rule 16b-3 | ||
Susan Wyrick over two months ago Disposition of 2565 shares by Susan Wyrick of Sana Biotechnology at 4.44 subject to Rule 16b-3 | ||
Susan Wyrick over two months ago Disposition of 10000 shares by Susan Wyrick of Sana Biotechnology subject to Rule 16b-3 | ||
Bishop Hans Edgar over three months ago Acquisition by Bishop Hans Edgar of 5628 shares of Sana Biotechnology subject to Rule 16b-3 |
Sana Biotechnology Notable Stakeholders
A Sana Biotechnology stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Sana Biotechnology often face trade-offs trying to please all of them. Sana Biotechnology's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Sana Biotechnology's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Steven MD | CEO President | Profile | |
| Nathan MBA | Executive CFO | Profile | |
| Susan Wyrick | Treasurer, CFO | Profile | |
| Sunil MD | Head VP | Profile | |
| Christian MBA | Executive Officer | Profile | |
| Aaron Grossman | Executive Officer | Profile | |
| Shanna Peek | Sr Operations | Profile | |
| Richard Mulligan | Executive Research | Profile | |
| Sonja MD | Senior Platform | Profile | |
| Gary MD | Chief Officer | Profile | |
| Farah Anwar | Head Operations | Profile | |
| John MD | Head Development | Profile | |
| Terry MD | Senior Therapeutics | Profile | |
| Yuko JD | Head Property | Profile | |
| Snehal Patel | Senior Officer | Profile | |
| Paul MD | Senior Science | Profile | |
| Edward Rebar | Head Engineering | Profile | |
| Brittany Mccleery | Accounting Mang | Profile | |
| Robin Andrulevich | Executive Officer | Profile | |
| Bernard JD | Exec Counsel | Profile |
About Sana Biotechnology Management Performance
The success or failure of an entity such as Sana Biotechnology often depends on how effective the management is. Sana Biotechnology management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Sana management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Sana management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company was incorporated in 2018 and is headquartered in Seattle, Washington. Sana Biotechnology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 461 people.
Please note, the presentation of Sana Biotechnology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Sana Biotechnology's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Sana Biotechnology's management manipulating its earnings.
Sana Biotechnology Workforce Analysis
Traditionally, organizations such as Sana Biotechnology use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Sana Biotechnology within its industry.Sana Biotechnology Manpower Efficiency
Return on Sana Biotechnology Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.4M | |
| Net Loss Per Executive | 13.3M | |
| Working Capital Per Employee | 594.7K | |
| Working Capital Per Executive | 5.8M |
Complementary Tools for Sana Stock analysis
When running Sana Biotechnology's price analysis, check to measure Sana Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sana Biotechnology is operating at the current time. Most of Sana Biotechnology's value examination focuses on studying past and present price action to predict the probability of Sana Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sana Biotechnology's price. Additionally, you may evaluate how the addition of Sana Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |